Cimetidine: Difference between revisions
| Line 23: | Line 23: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B (animal studies show no risk for adverse fetal effects, human fetal harm possible but unlikely) | ||
*Lactation: | *Lactation: Probably Safe | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult: CrCL 10-50: decrease dose 50%, CrCl <10, decrease dose 75% | ||
**Pediatric | **Pediatric: CrCl 20-40, decrease dose 25% or give q8h, CrCL <20: decrease dose 50% | ||
*Hepatic Dosing | *Hepatic Dosing | ||
**Adult | **Adult: Not Defined | ||
**Pediatric | **Pediatric not defined | ||
==Contraindications== | ==Contraindications== | ||
Revision as of 19:29, 25 March 2015
General
- Type: H2 Blocker
- Dosage Forms: 200, 300, 400, 800 mg
- Common Trade Names: Tagamet HB 200
Adult Dosing
Duodenal Ulcer, Active: 800 mg PO QHS x 4-8 weeks
Duodenal Ulcer, Maintenance: 400 mg PO QHS
Gastric Ulcer, active benign: 800 mg PO QHS x 6 weeks
H. Pylori Infection: 400 mg PO BID x 10-28 days
Pediatric Dosing
GERD/PUD:
* Neonates: 5- 10 mg/kg/day PO divided q8-12h * Infants: 10-20 mg/kg/day PO divided q8-12h * Children: 20-40 mg/kg/day PO divided q6H
Special Populations
- Pregnancy Rating: B (animal studies show no risk for adverse fetal effects, human fetal harm possible but unlikely)
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCL 10-50: decrease dose 50%, CrCl <10, decrease dose 75%
- Pediatric: CrCl 20-40, decrease dose 25% or give q8h, CrCL <20: decrease dose 50%
- Hepatic Dosing
- Adult: Not Defined
- Pediatric not defined
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action: